RxDoctor Payments Data

Dennis Fry, MD

Vascular Surgery · West Des Moines, IANPI 1427042449

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Medtronic at 40.4% of the total. Reporting peaked in 2022 at $4,673 and has fallen 86.7% since, to $623 in 2025.

$11,672in general payments, 2019–2025

Across 145 payments — averaging $80.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Abbott$3K
  • W. L. Gore & Associates, Inc.$2K
  • Bard Peripheral Vascular, Inc.$393
  • Endologix LLC$338
  • Inari Medical, Inc.$281
  • plus $803 from 10 others
$2,350in research payments, 2019–2025

Across 2 payments — averaging $1175.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bard Peripheral Vascular, Inc.$2K
  • Philips North America LLC$250

What the payments were for

  • Speaking & faculty fees$1,95017%
  • Travel & lodging$4,10935%
  • Food & beverage$5,55948%
  • Education$530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,672 in reported general payments places this provider in the 75th percentile of 38 vascular surgery providers in Iowa.

See all vascular surgery providers in Iowa

Medicare billing

Part B allowed, 2024
$455,621
Medicare patients
1,215
Services billed
2,335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$11,457
ClopidogrelClopidogrel Bisulfate113$636
Atorvastatin Calcium14$35

Paid to pharmacies, not to this prescriber.

Other vascular surgery in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →